Digoxin and Foetal growth restriction - a phase IV clinical study of FDA data

Summary:

Foetal growth restriction is reported as a side effect among people who take Digoxin (digoxin), especially for people who are 30-39 old, also take Warfarin Sodium, and have Foetal exposure during pregnancy.

The phase IV clinical study analyzes which people have Foetal growth restriction when taking Digoxin. It is created by eHealthMe based on reports of 92,292 people who have side effects when taking Digoxin from the FDA, and is updated regularly.

What is Digoxin?

Digoxin has active ingredients of digoxin. It is often used in atrial fibrillation/flutter. eHealthMe is studying from 93,740 Digoxin users. Check the latest studies of Digoxin.

What is Foetal growth restriction?

Foetal growth restriction (poor growth of a baby while in the mother's womb during pregnancy) is found to be associated with 368 drugs and 449 conditions by eHealthMe. Check the latest studies of Foetal growth restriction.

On Jul, 09, 2026

92,292 people reported to have side effects when taking Digoxin.
Among them, 22 people (0.02%) have Foetal growth restriction.

Could Digoxin cause Foetal growth restriction?

Among these 22 people:

What is the age of people who have Foetal growth restriction when taking Digoxin? *

What are other drugs people take besides Digoxin? *

What are other side effects people have besides Foetal growth restriction? *

Foetal Exposure During Pregnancy (exposing your unborn child to contraindicated in pregnancy leads birth defect): 12 people, 54.55%
Premature Baby: 10 people, 45.45%
Low Birth Weight Baby: 8 people, 36.36%
Wound Haemorrhage (bleeding wound): 5 people, 22.73%
Premature Rupture Of Membranes: 5 people, 22.73%
Mediastinal Haemorrhage (bleeding in mediastinum): 5 people, 22.73%
Premature Labor: 5 people, 22.73%
Maternal Exposure During Pregnancy (use of substance during pregnancy): 5 people, 22.73%
Pulmonary Arterial Pressure Decreased: 5 people, 22.73%
Cardiac Failure: 2 people, 9.09%

What are the existing conditions these people have? *

Foetal Exposure During Pregnancy (exposing your unborn child to contraindicated in pregnancy leads birth defect): 5 people, 22.73%
Ejection Fraction Decreased (systolic heart failure): 2 people, 9.09%
Orthopnea (shortness of breath (dyspnea) when lying down): 1 person, 4.55%
Oedema (fluid collection in tissue): 1 person, 4.55%
Menstruation Irregular: 1 person, 4.55%
Menopause (end of monthly cycles in women): 1 person, 4.55%
Menopausal Symptoms: 1 person, 4.55%
Haemodynamic Instability (disturbances in the blood movement in our body): 1 person, 4.55%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 4.55%
Foetal Heart Rate Decreased: 1 person, 4.55%

* Approximation only. Some reports may have incomplete information.

Do you take Digoxin and have Foetal growth restriction?

- Check whether Foetal growth restriction is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Digoxin:

Digoxin (93,740 reports)

Browse all side effects of Digoxin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Foetal growth restriction:

Foetal growth restriction (368 drugs)

Browse all the conditions that are associated with Foetal growth restriction:

Foetal growth restriction (449 conditions)

Related publications that referenced our studies

Guru SR, Suresh A, Padmanabhan S, Reddy A, "A Rare Case of Digoxin Associated Gingival Overgrowth", Journal of clinical and diagnostic research: JCDR, 2017 Jan .
Lai SW, Lin CL, Liao KF, "Digoxin use may increase the relative risk of acute pancreatitis: a population-based case–control study in Taiwan", International journal of cardiology, 2015 Feb .
Guru SR, Suresh A, Padmanabhan S, Reddy A, "A Rare Case of Digoxin Associated Gingival Overgrowth", Journal of clinical and diagnostic research: JCDR, 2017 Jan .
Lai SW, Lin CL, Liao KF, "Digoxin use may increase the relative risk of acute pancreatitis: a population-based case–control study in Taiwan", International journal of cardiology, 2015 Feb .

How the study uses the data?

The study uses data from the FDA. It is based on digoxin (the active ingredients of Digoxin) and Digoxin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.